Article

Carolyn Presley on the Implications of Screening on Lung Cancer Care

Author(s):

Carolyn Presley

Carolyn Presley discusses the implications of screening on diagnosis and treatment of lung cancer.

Carolyn Presley, clinical fellow, geriatric oncology, Yale Cancer Center, Robert Wood Johnson Clinical Scholar, discusses the implications of screening on diagnosis and treatment of lung cancer.

Read more about the study.

Related Videos
There are a number of reasons why patients with cancer are encouraged to enroll in clinical trials, Dr. Michael J. Pishvaian explained.
Use of NeuroSAFE to guide nerve sparing during robot-assisted radical prostatectomy improved patient-reported erectile function.
Adolescent and Young Adult Cancer Awareness Week sheds light on the financial hardships young cancer survivors face, including debt and limited assistance.
CURE spoke with Dr. William C. Huang about what kind of team may be required to treat a patient with metastatic kidney cancer.
Image of woman.
Image of woman.
Image of woman.
Image of man wearing baseball cap backwards.
Image of smiling doctor.
Registered nurse Patricia Jakel emphasizes the importance of educating patients on evolving breast cancer research and the need for routine screenings.
Related Content
Illustratoin of lungs
April 2nd 2025

Camrelizumab Combo Doubles 5-Year Survival in Phase 3 Lung Cancer Trial

Spencer Feldman
Camrelizumab combo doubled the five-year survival rate in advanced squamous lung cancer, reducing mortality risk by 43%, in a Phase 3 trial.
CURE Cancer Horizons logo
February 26th 2024

FDA Approvals from February 2024

Alex Biese Brielle Benyon
February brought in multiple FDA approvals in the oncology space. Here’s an overview of some of the most recent ones.
Image of lung.
March 31st 2025

COCOON Trial Regimen Reduces Dermatologic Side Effects in Mutated Lung Cancer

Spencer Feldman
The COCOON trial regimen reduced dermatologic side effects in patients with EGFR-mutant non-small cell lung cancer, phase 2 trial data showed.
Guidelines for Childhood Neuroblastoma, FDA Decisions and More
February 12th 2024

Guidelines for Childhood Neuroblastoma, FDA Decisions and More

Alex Biese Brielle Benyon
Last week, we saw a few moving parts in the regulatory space, from new NCCN guidelines for pediatric neuroblastoma treatment to FDA Fast Tracks and Priority Reviews
Illustration of tumor.
March 28th 2025

Solnerstotug Demonstrates Early Efficacy in PD-L1 Resistant Tumors

Spencer Feldman
Favorable initial results from a phase 1/2 trial of solnerstotug in PD-L1–resistant tumors showed a 14% response rate and 62% disease control rate.
CAN-2409 elicited responses among patients with pretreated stage 3/4 non–small cell lung cancer: © steph_photographis - stock.adobe.com
March 27th 2025

CAN-2409 Elicits Survival Responses In NSCLC

Alex Biese
Treatment with CAN-2409, an off-the-shelf immunotherapy, elicited responses among patients with pretreated stage 3/4 non–small cell lung cancer.